We conducted a systematic review to determine the appropriate use of bortezomib alone or
in combination with other agents in patients with multiple myeloma (MM). We searched …

This overview summarizes evidence for the efficacy and safety of bortezomib, thalidomide,
and lenalidomide in patients with multiple myeloma. We searched the Medline, Scopus, and …

Over the past decade, use of novel agents, including immunomodulatory drugs (IMiDs) and
proteasome inhibitors (PIs) has resulted in high response rates and improvement in overall …

Novel anti-myeloma agents have improved patient response rates, which are historically
based on reductions of the M-protein. These methods can be inaccurate for quantifying M …

The impact of age, ethnicity and socio‐economic deprivation in the era of novel anti‐
myeloma agents is unclear. Using linked national data from New Zealand, we evaluated the …

OBJECTIVES: The current approach for evaluating the risk of random error in meta-analyses
(MAs) using trial sequential analysis (TSA) can accommodate binary and continuous data …

The aim of this study was to evaluate the impact of the response to induction therapy on the
long-term prognosis of multiple myeloma (MM) after autologous stem cell transplantation …

Introduction Bortezomib has significantly improved multiple myeloma (MM) response rates,
but strategies for choosing bortezomib-based regimens for initial MM therapy are not …

Trial sequential analysis (TSA) has been proposed as a method to assess the risk of random
error in cumulative meta-analysis (MA), which increases due to repeated significance …

Background/Purpose Multiple myeloma (MM) is a monoclonal plasma cell malignancy. The
primary choice of treatment for MM is induction therapy followed by autologous stem cell …